Navigation Links
Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
Date:11/1/2007

WALTHAM, Mass., Nov. 1 /PRNewswire/ -- Proteon Therapeutics (http://www.proteontherapeutics.com), a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, is presenting tomorrow at the Annual Meeting of the American Society of Nephrology an abstract entitled "Recombinant Human Elastase (PRT-201) Dilates Outflow Veins in a Preclinical Model of Arteriovenous Fistula." Findings to be presented represent an important preclinical demonstration of the potential of PRT-201 to enhance arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. It is well documented that between 30 and 50 percent of AVFs, the preferred form of vascular access, fail to mature to usable access sites for dialysis patients.

"Vascular access related complications are a major cause of suffering and hospitalization for dialysis patients," said Timothy P. Noyes, the Company's President and CEO. "We believe that PRT-201 could potentially facilitate the creation of more reliable dialysis access sites."

About Vascular Access in Hemodialysis

Patients with end stage kidney disease must undergo periodic external blood filtering by hemodialysis machines in order to remove fluid and metabolic byproducts from their blood. Vascular surgeons prepare patients for hemodialysis by creating access sites in the body that can be connected to hemodialysis machines. These high flow access sites are usually created by connecting an artery to a vein, resulting in a "shunt" of blood from the artery to the vein. There are three main types of chronic hemodialysis access sites: Arteriovenous fistulas are created by connecting veins directly to arteries, arteriovenous grafts are created by connecting veins to arteries with a segment of artificial tubing, and catheters are placed directly in large vein
'/>"/>

SOURCE Proteon Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... to accelerate commercialization,of personal care ingredients with its proprietary oleosome-based technology ... ... ... Inc. (,Botaneco,), a wholly-owned subsidiary of SemBioSys,Genetics Inc. (,SemBioSys,), today announced that it has ...
... June 30 Exiqon A/S today,received information from Danske ... Livsforsikring and Danske Fund FCP - through,acquisition today of ... of each DKK 1 corresponding to 5,99% of the ... A/S., About Exiqon, Exiqon,s corporate mission is ...
... funding over 10-year ... life of competition, PITTSBURGH, June 27 ... Park Prime,Steakhouse on Pittsburgh,s North Shore Olive earlier this week marking an,end ... total,of $82,500 was awarded throughout all phases this year., The competition ...
Cached Biology Technology:Botaneco announces $4,000,000 financing 2Botaneco announces $4,000,000 financing 3Botaneco announces $4,000,000 financing 4EnterPrize Business Plan Competition Announces Final Phase Winners of Cash Awards Totaling $45,000 2
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
... have long known that the social insects in ... an unusual mechanism for sex determination: Unfertilized eggs ... But the development of an unfertilized egg into ... , One mystery has been the origin ...
... Florida State University scientist used a gene transfer technique ... clinical depression in a new study of mice that ... this condition. , Carlos Bolanos, an assistant professor of ... that identified the role of a gene called Brain ...
... the Universtity of Helsinki, Finland, came together to advance ... controlled. The results of this work are published in ... reached in 2001 when sequencing of the human genome ... read-outs of DNA sequence for several species, for example ...
Cached Biology News:Insects that produce males from unfertilized eggs reveal a surprising cellular feat 2Insects that produce males from unfertilized eggs reveal a surprising cellular feat 3It's in the genes: Study opens door to new treatment of the blues 2Cracking the genetic code for control of gene expression 2
...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Form: Concentrated Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: